After reaching a resting state on day 10–12, transduced CD4+ T cells were re-stimulated with K562 (myelogenous leukemia line) target cells that were modified to express HLA-A2, GFP, and the NY-ESO-1 antigen [36]. The gene discussed is CD4; the disease is myeloid leukemia.